Creative Biolabs Expands Antibody Engineering Services to Cover Non-IgG Therapeutic Antibodies
As non-IgG antibodies being proved to play a role in various kinds of cancers and chronic inflammation, Creative Biolabs introduces non-IgG therapeutic antibody engineering services to help accelerate customers’ obtaining ideal results in their projects.
New York, United States – September 13, 2021 /MarketersMEDIA/ —
Recently, researchers found that IgA is effective in recruiting neutrophils for tumor cell killing and is potently active against several pathogens, including SARS-CoV-2, which makes non-IgG (mainly IgM, IgE, or IgA) antibody a hot topic in the field of bio-science. Having accumulated much experience in IgG antibody development, Creative Biolabs now extends the business portfolio to non-IgG therapeutic antibody engineering and production, which exhibit several features and advantages over IgG antibodies.
· Humanized Non-IgG Antibody Engineering Service
At Creative Biolabs, the humanization of non-IgG antibody is conducted via complementarity-determining region (CDR) grafting at the DNA level. Once clients providing non-IgG antibodies, scientists will start with DNA sequence determination of the non-IgG antibody CDRs and provide professional humanization services based on the advanced technology platform.
The humanized non-IgG antibodies engineering services mainly include antibody humanization design, vector synthesis and cloning, transient expression, and stable expression of cell lines, covering a wide range of antibody species and promising constant quality with a high level of affinity and specificity.
· Glycosylated Non-IgG Antibody Service
With accumulated knowledge and experience in developing therapeutic antibodies, the scientist team at Creative Biolabs is skillful at glycosylation modifications especially to the Fc or Fab region, which can improve effector functions and have a significant impact on the therapeutic antibody’s diversity, safety, immunogenicity, stability, and clinical efficacy.
An antibody glycoengineering platform is now constructed to provide high-quality non-IgG antibody glycosylation characterization and glycan profiling services.
· Non-IgG Antibody Drug Conjugate Service
Creative Biolabs has been striving to produce Antibody Drug Conjugate (ADC), and is now capable of delivering non-IgG antibodies drug conjugation design and development services. The services include but are not limited to non-IgG antibody services, linker and conjugation services, as well as in vitro and in vivo evaluation services.
In especial, with the established DrugLnkᵀᴹ platform, the linker and conjugation services can contain custom ADC linkers’ synthesis and modification services, assuring that the effective drug and selected non-IgG antibodies are assembled through an appropriate linker.
Besides the aforementioned services, Creative Biolabs also offers chimeric non-IgG antibody engineering service, bi-specific non-IgG antibody service, half-life extension services, antibody isotype switching service, etc. Further information can be found at https://non-igg-ab.creative-biolabs.com/.
About Creative Biolabs
Empowered by leading technology and years of experience in biomedical science, Creative Biolabs is skilled at providing therapeutic non-IgG antibody-related services with the help of the cutting-edge Antibody GlycoOpitimize Platform and Expression System Platform. The one-stop services range from non-IgG antibody discovery, engineering, production and purification to characterization and PK/PD evaluation.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://non-igg-ab.creative-biolabs.com/
Source: MarketersMEDIA
Release ID: 89045136
Copyright © 1999-2013 SproutNews.com
